Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography

Mirella L. Altoe, Kevin Kalinsky, Alessandro Marone, Hyun K. Kim, Hua Guo, Hanina Hibshoosh, Mariella Tejada, Katherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Dawn L. Hershman, and Andreas H. Hielscher

Abstract

Background: The purpose of this study is to evaluate whether the changes in optically derived parameters acquired with a diffuse optical tomography breast imager system (DOTBIS) in the contralateral non-tumor-bearing breast in patients administered neoadjuvant chemotherapy (NAC) for breast cancer are associated with pathologic complete response (pCR).

Methods: In this retrospective evaluation of 105 patients with stage II–III breast cancer, oxy-hemoglobin (ctO$_2$Hb) from the contralateral non-tumor-bearing breast was collected and analyzed at different time points during NAC. The earliest monitoring imaging time point was after 2–3 weeks receiving taxane. Longitudinal data were analyzed using linear mixed-effects modeling to evaluate the contralateral breast ctO$_2$Hb changes across chemotherapy when corrected for pCR status, age, and BMI.

Results: Patients who achieved pCR to NAC had an overall decrease of 3.88 μM for ctO$_2$Hb (95% CI, 1.39 to 6.37 μM), p = .004, after 2–3 weeks. On the other hand, non-pCR subjects had a non-significant mean reduction of 0.14 μM (95% CI, –1.30 to 1.58 μM), p > .05. Mixed-effect model results indicated a statistically significant negative relationship of ctO$_2$Hb levels with BMI and age.

Conclusions: This study demonstrates that the contralateral normal breast tissue assessed by DOTBIS is modifiable after NAC, with changes associated with pCR after only 2–3 weeks of chemotherapy.

Keywords: Diffuse optical tomography, Breast cancer, Contralateral breast, Menopausal status, NAC, pCR
improved clinical outcomes, such as disease-free survival, and can predict disease recurrence across different breast cancer subtypes [1–3].

Relatively inexpensive, simple to operate, and well-tolerated by patients, diffuse optical tomography (DOT) has shown promising applications in breast cancer detection and monitoring NAC [4–8]. However, the measurement of optically derived parameters in the affected breast is strongly dependent on the tumor location, and DOT suffers from low spatial resolution due to its non-linear, ill-conditioned, and ill-posed inverse problem [9].

Using an a priori provided information by an additional high-resolution anatomical imaging modality, such as magnetic resonance or X-ray, could improve spatial resolution but also nullify the low-cost benefit associated with DOT techniques [10]. Therefore, DOT quantitative measure from the contralateral breast could offer a non-tumor dependent measurement to monitor NAC induced changes in the breast tissue and assess treatment outcome. Evaluation of optically derived parameters variation in the contralateral non-tumor-bearing breast following NAC has been previously analyzed [11]. Still, no extensive analyses have been performed to evaluate whether these changes are associated with tumor response in the affected breast. A study published in 2005 [12] reported that chemotherapy could decrease contralateral breast cancer risk in younger women [13]. However, assessment of chemotherapy-related benefits for developing a newly detected breast cancer is still a challenge due to the absence of accurate quantitative metrics.

Over the last decade, our group has developed a diffuse optical tomography breast imaging system (DOTBIS) for a full 3-dimensional tomographic assessment of the entire breast volume and simultaneous bilateral breast imaging. DOTBIS data acquisition is performed up to 32 sources and 64 detectors, depending on the patient interface consists of two sets of four rings that laser diodes operating at 765, 808, 827, and 905 nm. The infrared light transmission was carried out using four additional features such as scattering-dominated media as the breast tissue. Measurements were performed by a continuous wave dynamic imaging system (i.e., DOTBIS) that provides full three-dimensional tomographic images of both breasts simultaneously without requiring the use of contrast agents or compression. A more detailed description of the system can be found in previous reports [15, 17]. Total measurement time varied between 6 and 8 min in addition to 5 min required to set up the machine. Near-infrared light transmission was carried out using four laser diodes operating at 765, 808, 827, and 905 nm. The patient interface consists of two sets of four rings that use up to 32 sources and 6 detectors, depending on the patient’s breast cup size, for optical data collection. The spatial distribution of chromophore concentration of ctO2Hb, ctHHb, and water was obtained by a transport-theory-based PDE-constrained multispectral model [18], which uses the diffusion approximation of the equation of radiative transfer to describe the light propagation in such scattering-dominated media as the breast tissue. Additional features such as ctTHb and StO2% were defined respectively as Eq. (1) and Eq. (2). For visualization, maximum intensities projections (MIP) [19, 20] were obtained from the reconstructed 3D chromophore concentration maps. MIP projects the acquired data volume into a view plane, which can be obtained by finding the voxels with maximum intensity along a chosen axis, Fig. 1.

\[
ctTHb = ctO2Hb + ctHHb
\]

\[
StO2\% = \frac{ctO2Hb}{ctTHb} \times 100\%
\]

NAC imaging protocol

Sixty-nine patients received 12 cycles of weekly paclitaxel (with or without the addition of carboplatin) followed by four cycles of doxorubicin and cyclophosphamide given every 2 weeks with growth factor support (T × 12/AC ×...
4 or T/C × 12/AC × 4), and DOTBIS bilateral measurement was acquired at six different time points: before starting NAC regimen (TP0), after 2 weeks of taxane infusions (TP1), after 4 weeks of taxane (TP2), at the end of the taxane regimen and before starting AC cycles (TP3), after two cycles of AC (TP4), and at the end of NAC and before surgery (TP5). Thirty-six patients received other taxane-based NAC regimens without an anthracycline, and bilateral imaging was performed only three times (baseline (TP0), 2–3 weeks after the first taxane infusion (TP1), and at the end of NAC and before surgery (TP5)), Fig. 2.

Statistical analysis
An independent-samples t test was run to determine if there were differences in baseline DOTBIS parameters between pre-and postmenopausal subjects and pCR status (pCR and non-pCR patients). Feature importance was calculated by using Random Forest [21] modelspecific metrics from the R package “caret” [22]. The Random Forest algorithm has a built-in feature selection, mean decrease Gini (Gini importance) [23], which can be used as a score that provides a relative ranking of feature relevance. A paired-samples t test was used to determine whether there was a statistically significant mean difference in ctO$_2$Hb levels measured at baseline and TP1 between pCR and non-pCR and between both menopausal groups. To account for repeated measures, a linear mixed-effect model was designed to evaluate if there is a difference in the average longitudinal evolution of ctO$_2$Hb when we correct for pCR status (or age and BMI). Significance was assumed at a confidential interval of 95% ($\alpha = 0.05$).

Result
Patient summary
From a total of 105 subjects, 18 were excluded from the final analysis data set. The main reasons for exclusion were as follows: patient withdrew from the study ($n = 4$), baseline DOTBIS measurement not collected due to

---

**Fig. 1** Visual scheme of how maximum intensity projection (MIP) images are generated from the DOTBIS acquired ctTHb 3D map (μM). MIP is obtained by finding the maximum intensity for each voxel along the y-axis direction. The maximum voxel values are registered into a single view plane for visualization purposes only.

**Fig. 2** DOTBIS bilateral measurements were acquired at six or three different time points depending on the NAC regimen. For patients under T × 12/AC × 4 and T/C × 12/AC × 4 therapies ($n = 69$), contralateral non-tumor-bearing breast and the breast bearing the tumor were imaged at baseline (TP0), 2 weeks after the first taxane infusion (TP1), after four infusions of taxane (TP2), at the end of the taxane regimen and before starting AC cycle (TP3), after two AC infusions (TP4), and at the end of NAC and before surgery (TP5). For other taxane-based NAC regimens ($n = 36$), both breasts were imaged only three times: TP0, 2–3 weeks after the first taxane infusion (TP1), and TP5.
instrumentation failure \((n = 8)\), patient receiving non-FDA approved drug regimen \((n = 1)\), bilateral breast cancer \((n = 1)\), and machine operator error \((n = 4)\). Not all the patients had their DOTBIS reconstruction available for all of their imaging time points due to patient declining imaging at that particular DOTBIS time point or machine malfunction. Overall, 81 (93.1%) patients had DOTBIS images successfully reconstructed at baseline (TP0), 69 (79.3%) patients at 2–3 weeks from taxane initiation (TP1), and 52 (59.8%) at the pre-surgical time point (TP5). Missing TP5 data points were due to patient declined to be imaged (18/35), machine operator did not collect/save the data correctly (5/35), and data not collected due to machine under repair (12/35). Out of the 58 patients who were administered the \(T \times 12/AC \times 4\) \((n = 54)\) regimen or \(T/C \times 12/AC \times 4\) \((n = 4)\), 46 (79%) had their data acquired and reconstructed at TP2, 43 (74%) at TP3, and 40 (69%) at TP4. Non-anthracycline regimens accounted for the remaining 29 patients. Patient and clinical characteristics are summarized in Table 1.

### Baseline DOTBIS-measured features

Contralateral \(cTThb\), \(cO_2Hb\), \(cTHb\), water, and \(StO_2\) values were available for all the 87 patients considered for analysis at different time points across NAC. At the baseline level, there was no statistical difference in any of the DOTBIS-measured features between \(pCR\) and non-\(pCR\) patients \((p > 0.05)\). Fifty-two patients (59.8%) were premenopausal women, 34 (39.1%) were postmenopausal, and for one patient (1.1%), her menopausal status was uncertain. An independent samples \(t\) test was run to determine if there were differences in baseline DOTBIS parameters between pre- and postmenopausal subjects. Pre-menopausal women had higher mean \(cTThb\) \((33.30 \pm 12.22 \mu M)\) than post-menopausal women \((24.92 \pm 7.78 \mu M)\), a statistically significant difference of 8.39 \(\mu M\) (95% CI, 3.96 to 12.81), \(t(79) = 3.772, p < .0005\). \(cO_2Hb\) levels were also higher for pre-menopausal women \((19.36 \pm 8.51 \mu M)\) than postmenopausal \((13.24 \pm 4.89 \mu M)\). The difference in means for water was also statistically significant between pre- \((48.37 \pm 9.33\%)\) and postmenopausal \((40.48 \pm 12.14\%)\) patients, \(p = .001\).

### Contralateral breast DOTBIS feature selection

To avoid severe multicollinearity or overfitting, variable importance with random forest was performed to find the most relevant \(pCR\) status classification feature.

### Table 1

| Patient and clinical characteristics | Number of patients | Age (mean ± SD) | BMI (mean ± SD) |
|-------------------------------------|-------------------|----------------|-----------------|
| **Chemotherapy and targeted therapies** |                   |                |                |
| \(T \times 12/AC \times 4\)       | 54                | 48.48 ± 11.52  | 29.89 ± 7.18   |
| \(TCHP \times 6\)                  | 21                | 53.80 ± 10.04  | 29.307 ± 9.49  |
| \(TC \times 6\)                    | 6                 | 59.67 ± 12.24  | 30.54 ± 3.24   |
| \(T/C \times 12/AC \times 4\)     | 4                 | 39.25 ± 8.65   | 30.05 ± 2.29   |
| \(TC \times 4\)                    | 1                 | 30              | 18.11          |
| \(THP \times 12/AC \times 4\)     | 1                 | 40              | 32.23          |
| **Menopausal status**              |                   |                |                |
| Premenopausal                      | 52                | 41.65 ± 6.90   | 29.48 ± 7.91   |
| Postmenopausal                     | 34                | 61.63 ± 6.00   | 30.10 ± 6.82   |
| Uncertain                          | 1                 | 56              | 27.16          |
| **Tumor characteristics**          |                   |                |                |
| Treatment response classification  |                   |                |                |
| \(pCR\)                            | 36                |                |                |
| RCB 0                              | 36                |                |                |
| Non-\(pCR\)                        |                   |                |                |
| RCB I                              | 10                |                |                |
| RCB II                             | 27                |                |                |
| RCB III                            | 11                |                |                |
| RCB score not available            | 3                 |                |                |

**Abbreviations and acronyms:** \(T \times 12/AC \times 4\), 12 cycles of weekly paclitaxel followed by 4 cycles of doxorubicin and cyclophosphamide given every 2 weeks with growth factor support; \(T/C \times 12/AC \times 4\), 12 cycles of weekly paclitaxel followed by 4 cycles of doxorubicin and cyclophosphamide given every 2 weeks with growth-factor support with an addition of carboplatin to paclitaxel; \(TC \times 6\), six cycles Cytoxan plus Taxotere; \(TC \times 4\), four cycles Cytoxan plus Taxotere; \(TCHP\), six cycles of docetaxel, carboplatin, and trastuzumab plus pertuzumab; \(THP/AC\), paclitaxel, trastuzumab, and pertuzumab followed by doxorubicin and cyclophosphamide; \(pCR\), pathologic complete response; RCB, residual cancer burden; BMI, body mass index; SD, standard deviation
Looking at the changes of all the DOTBIS-measured features after 2–3 weeks under NAC, $ctO_{2}Hb$ was selected as the best predictor characterized by the highest mean decrease impurity (Gini importance). For this feature, lower values are associated with poor response to NAC (non-pCR).

$ctO_{2}Hb$ changes in the contralateral breast after 2–3 weeks under NAC and pCR status

Thirty-seven subjects (42.5%) achieved pCR and 50 (57.5%) were classified as non-pCR. A paired $t$ test was used to determine whether there was a statistically significant mean difference between baseline $ctO_{2}Hb$ and after 2–3 weeks under NAC (TP1). Overall, NAC elicited a mean decrease of 1.57 μM for $ctO_{2}Hb$ levels (95% CI, 0.28 to 3.32 μM), $t(67) = 2.43, p = .022$, in the contralateral non-tumor-bearing breast. Looking at the pCR group, NAC elicited an overall decrease of 3.88 μM for $ctO_{2}Hb$ (95% CI, 1.39 to 6.37 μM), $p = .004$. On the other hand, the non-pCR subjects had a non-significant mean reduction of 0.14 μM for $ctO_{2}Hb$ (95% CI, −1.30 to 1.58 μM), $p = .845$, Fig. 3.

c$to_{2}Hb$ longitudinal analysis in the contralateral breast during NAC: pCR status, age, and BMI as model predictors

For the longitudinal multilevel mixed-effects analysis, $ctO_{2}Hb$ from all patients ($n = 87$) was analyzed at three time imaging points, TP0, TP1, and TP5, which are the imaging time points in common to all the patients regardless of their chemotherapy regimen. We fit a linear mixed-effects model with $ctO_{2}Hb$ as the outcome variable, with fixed effects of pCR status, BMI and age, and time as a random effect (and fixed effect) and random slope across individuals. We were also particularly interested in the group-occasion interaction between time and pCR status, as this reflects a potential difference in time evolution between the pCR status groups. There was a significant interaction between $ctO_{2}Hb$ over time and pCR status. pCR patients had a significant reduction in $ctO_{2}Hb$ levels at TP1 (3.53 μM, $p = .0053$) than non-pCR, but not statistically significant at TP5 (2.59 μM, $p = .131$). This trend can also be observed in the iteration plot of $ctO_{2}Hb$ levels over the different time points for both pCR and non-pCR groups, Fig. 4. Significant main effects of age ($p = .0015$) and BMI ($p = .0011$) were also found, Table 2, characterized by a negative relationship, older and overweighted patients had lower $ctO_{2}Hb$ levels. Figure 5 (pCR) and Fig. 6 (non-pCR) illustrate the hemoglobin map for two premenopausal patients imaged at three different time points during NAC regimen.

Discussion

We investigated whether the changes of DOTBIS features in the contralateral healthy breast are associated with therapy outcome in patients with stage II–III breast cancer receiving NAC. We observed that hemoglobin level is modifiable throughout the course of NAC. The magnitude of change is associated with pCR after only 2–3 weeks with the initiation of a taxane-based regimen. Patients who achieved a pCR to NAC had a more significant reduction in DOTBIS-measured features than the non-pCR group.

Previous studies have demonstrated statistically significant changes in optically derived parameters in breast cancer patients undergoing NAC and their correlation with tumor response [5, 14, 24–28]. However, most of these studies looked at the tissue composition of the tumor volume, and few of them only used the contralateral healthy breast data as a normalizing factor for the total tissue hemoglobin concentration within the tumor region. The measurement of optically derived parameters in the affected breast is strongly dependent on selecting the tumor location or region of interest (ROI). Yet, it is well known that breast optical imaging has limitations regarding spatial resolution. Therefore, the optically derived parameters collected from the
The contralateral unaffected breast can offer a more unbiased and non-ROI dependent measurement to follow up the course of changes in the breast tissue during NAC and associations with treatment outcome. The only two previous studies [11, 29], which evaluated optical imaging changes during NAC in the contralateral normal tissue, did not perform analyses regarding tumor response. By associating contralateral healthy breast data with tumor response, we could provide a potential marker for evaluating chemotherapy regimens’ efficacy early in the treatment course.

A similar association with pCR is also reported in the literature for background parenchymal enhancement (BPE) at breast magnetic resonance (MR) imaging in the contralateral normal breast. Several groups [30–33] have demonstrated an association between BPE and tumor response after receiving NAC in the last 4 years. Chen et al. found that BPE showed a significant decrease in those with pCR compared to non-pCR for pre/perimenopausal patients after starting NAC [30]. Next, Preibsch et al. investigated the influence of chemotherapy on the degree of BPE and found correlations between tumor response and qualitative assessment of BPE following NAC [31]. You et al. also reported a positive association between overall BPE reduction at the early stage of NAC and tumor response, especially in patients with hormone receptor-negative breast cancers [32].

Given enough evidence that optical imaging is a powerful tool to study the breast tissue’s structural and vascular properties [34], ctTHb and ctO$_2$Hb are thought to be correlated to the amount of blood flow in the fibroglandular tissue and represent breast vascular supply and perfusion. The significant large reduction of DOTBIS-measured features for the premenopausal group may be explained by the ovarian function suppression that affects estrogen secretion and leads to a secondary change in breast tissue composition and its vascular characteristics [35, 36]. A review published in

Table 2 Summary for the longitudinal model analysis: estimated model fixed effects

| Effect       | Estimate | Std. error | t     | p value   |
|--------------|----------|------------|-------|-----------|
| Intercept    | 33.41    | 3.65       | 9.15  | < 0.0005  |
| pCR status   | 0.76     | 1.61       | 0.47  | 0.64      |
| Time TP1     | –3.60    | 0.97       | –3.72 | 0.0003    |
| Time TP5     | –3.73    | 1.32       | –2.82 | 0.0056    |
| BMI          | –0.29    | 0.008      | –3.37 | 0.0011    |
| Age          | –0.17    | 0.052      | –3.39 | 0.0015    |
| TP1: pCR status | 3.53   | 1.24       | 2.84  | 0.0053    |
| TPS: pCR status | 2.59   | 1.70       | 1.52  | 0.1306    |

Abbreviations and acronyms: pCR, pathologic complete response; TP1, time point after 2–3 weeks under chemotherapy; TPS, time point after ending chemotherapy
Altoe et al. Breast Cancer Research (2021) 23:16

2005 [12] also concluded that younger women had much larger benefits from chemotherapy than older patients, potentially due to the ovarian ablation induced by chemotherapeutic agents. Fibroglandular tissue (FGT) and BPE-MRI were also reported as markedly influenced by menopausal status, significantly decreasing after menopause for most women included in the study [37]. On the other hand, substantial changes in DOTBIS-measured parameters for those with pCR regardless of their menopausal status could also be associated with the direct damage of the vascular morphology and density in normal tissue caused by chemotherapy, as investigated by Miller et al. [38].

Besides, the mixed-effect model results indicated a statistically significant negative relationship between \(cO_2Hb\) and BMI. DOTBIS-measured \(cO_2Hb\) is thought to be correlated to breast density since it is related to the arterial blood supply carrying oxygen to meet the fibroglandular tissue metabolic demand [29]. In contrast, BMI is inversely related to percent density and acts as a co-founder of each other’s effects [39–42]. In other words, overweight is correlated to a greater amount of fat in the breast, reflecting a larger non-dense tissue area in the mammogram and, consequently, lower percent density classification [41].

A limitation of our study was we did not reliably capture the patient’s menstrual period during treatment and around the time of scans. Besides that, since the majority of the patients in our study did not have breast MR imaging before and after NAC treatment, we were not able to expand our analyses to correlations between MR based quantitative measurements and DOTBIS features. Finally, a more extensive study is also required to identify potential optical predictors of long-term outcomes in breast cancer patients who undergo NAC and understand chemotherapy’s effect on reducing contralateral cancer risk.

**Conclusion**

In summary, this is the first study to confirm that optical derived metrics, measured by DOTBIS, in the contralateral non-tumor-bearing breast tissue, are modifiable with NAC treatment. \(cO_2Hb\) changes are proportional to the degree of pCR after 2–3 weeks of taxane-based regimen.

**Fig. 5** Corresponding hemoglobin levels map for the contralateral unaffected breast of 47-year-old women who achieved pCR after TCHP therapy for HER2+ breast cancer. MIP images (axial orientation) were acquired at baseline, after 2–3 weeks after NAC initiation (TP1), and at the pre-surgical time point (TP5).

**Fig. 6** Corresponding hemoglobin levels map for the contralateral unaffected breast of 46-year-old women classified as RCB III (non-pCR) after Tx12/ACx4 therapy for HER2- breast cancer. MIP images (axial orientation) were acquired at baseline, after 2–3 weeks of NAC (TP1), and at the pre-surgical time point (TP5).
Acknowledgements
Not applicable.

Authors’ contributions
 Provision of study materials or patients was made by KK, KDC, MKM, MST, and DLH. MLA and MT were responsible for data collection and imaging. MLA, AM, and HKK were responsible for data processing and interpretation. HG and HH analyzed the pathological clinical samples. MLA, KK, DLH, and AHV were responsible for data analysis and interpretation. HH and AH wrote the manuscript with assistance from the other authors. All authors read and approved the final manuscript.

Funding
This work was supported in part by a grant from the Columbia Biomedical Engineering Technology Accelerator (BiomedX) and the Breast Cancer Research Foundation. Kevin Kalinsky was supported in part by the Irving Institute for Clinical and Translational Research at Columbia University in the City of New York.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All subjects provided informed written consent and participated in this study. Ethics approval and consent to participate

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Departments of Biomedical Engineering, New York University Tandon School of Engineering, Brooklyn, NY 11201, USA. 2Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY 10032, USA. 3Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA. 4Department of Epidemiology, Columbia University Irving Medical Center, New York, NY 10032, USA.

Received: 5 May 2020 Accepted: 20 January 2021
Published online: 31 January 2021

References
1. Cortazar P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the ICON08C pooled analysis. Lancet. 2014; 384(9938):164–72. https://doi.org/10.1016/S0140-6736(13)62422-8.
2. Bonadonna G, Valagussa P, Brambilla C, Ferrari L. Preoperative chemotherapy in operable breast cancer. Lancet. 1993;341(8858):1485. https://doi.org/10.1016/0140-6736(93)90938-Z.
3. Cameron DA, et al. Primary systemic therapy for operable breast - 10-year survival data after chemotherapy and hormone therapy. Br J Cancer. 1997;76(8):1099. https://doi.org/10.1038/bjc.1997.541.
4. B. J. Tromberg, B. W. Pogue, K. D. Paulsen, A. G. Yodh, D. A. Boas, and A. E. Cerussi, “Assessing the future of diffuse optical imaging technologies for breast cancer management,” Med. Phys., 35, no. 6Part1, pp. 2443–2451, 2008, doi: https://doi.org/10.1118/1.2919078.
5. Cerussi A, et al. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad Sci U S A. 2007;104(10):4014–9. https://doi.org/10.1073/pnas.0611058104.
6. Cong W, Intes X, Wang G. Optical tomographic imaging for breast cancer detection. J Biomed Opt. 2017;22(9):1–6. https://doi.org/10.1117/1.JBO.22.9.096011.
7. Gunther JE, et al. Dynamic diffuse optical tomography for monitoring neoadjuvant chemotherapy in patients with breast cancer. Radiology. 2018; 287(3):778–86. https://doi.org/10.1148/radiol.2018161041.
8. Choe R, et al. Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. J Biomed Opt. 2009;14(2):024020. https://doi.org/10.1117/1.3109325.
9. Chance B, Cooper CE, Delpy DT, Reynolds EOR, Arridge SR, Schweiger M. Image reconstruction in optical tomography. Philos Trans R Soc Lond Ser B Biol Sci. 1997;352(1354):717–26. https://doi.org/10.1098/rstb.1997.0054.
10. Azizi L, Zareyacht K, Ettori D, Tinet E, Tuille J-M. Ultimate spatial resolution with diffuse optical tomography. Opt Express. 2009;17(14):12132–44. https://doi.org/10.1364/OE.17.012132.
11. O’Sullivan TD, et al. Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy. Breast Cancer Res. 2013;15(1):R14. https://doi.org/10.1186/bcr3389.
12. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–710. https://doi.org/10.1016/S0140-6736(05)66544-0.
13. Shahedi K, Emanuelsen M, Winkland F, Gronberg H. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma. Cancer. 2006;106(6):1237–42. https://doi.org/10.1002/cncr.21753.
14. Lim EA, et al. Diffuse optical tomographic imaging correlates with residual tumor burden after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2017;162(3):533–40. https://doi.org/10.1007/s10549-017-4150-7.
15. Flexman ML, et al. Optical biomarkers for breast cancer derived from dynamic diffuse optical tomography. J Biomed Opt. 2013;18(9):096012. https://doi.org/10.1117/1.4809601.
16. Symmans WF, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(28):4414–22. https://doi.org/10.1200/JCO.2007.10.6623.
17. Flexman ML, et al. Digital optical tomography system for dynamic breast imaging. J Biomed Opt. 2011;16(7):076014. https://doi.org/10.1117/1. 3599995.
18. Kim HK, Flexman M, Yamashiro DJ, Kandel JJ, Hieslcher AH. PDE-constrained multispectral imaging of tissue chromophores with the equation of radiative transfer. Biomed Opt Express. 2010;1(3):812–24. https://doi.org/10.1364/BOE.1.000812.
19. Cody DD. AAPM/RSNA physics tutorial for residents: topics in CT. Radiographics. 2002;22(5):1255–68. https://doi.org/10.1148/rg.22.5.020m1255.
20. Prokop M, Shin HO, Schanz A, Schaefer-Prokop CM. Use of maximum intensity projections in CT angiography: a basic review. Radiographics. 1997; 17(2):433–51. https://doi.org/10.1148/rg.17.2.9084083.
21. Breiman L. Random forests. Mach Learn. 2001;45(1):5–32. https://doi.org/10.1023/A:1010934043424.
22. A. Liaw and M. Wiener, “Classification and regression by RandomForest,” Forest. 2003, Vol 2/3:18–22. https://www.r-project.org/doc/Rnews/ Rnews_2002-3.pdf.
23. Chen R-C, Dewi C, Huang S-W, Caraka RE. Selecting critical features for data classification based on machine learning methods. J Big Data. 2020;7(1):52. https://doi.org/10.1186/s40537-020-00327-4.
24. Choe R, Durduran T. Diffuse optical monitoring of the neoadjuvant breast cancer therapy. IEEE J Sel Top Quantum Electron Publ IEEE Lasers Electro-Opt Soc. 2012;18(4):1367–86. https://doi.org/10.1109/JSTQE.2012.2177963.
25. Zhou C, et al. Diffuse optical monitoring of blood flow and oxygenation in human breast cancer during early stages of neoadjuvant chemotherapy. J Biomed Opt. 2007;12(5):051903. https://doi.org/10.1117/1.2798595.
26. Ueda S, et al. Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. Cancer Res. 2012;72(17):4318–28. https://doi.org/10.1158/ 0008-5472.CAN-12-0056.
27. Jiang S, et al. Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. Radiology. 2009;252(2):551–60. https://doi.org/10.1148/radiol.2522081202.
28. Cerussi AE, Tanamai VW, Hsiang D, Butler J, Mehta RS, Tromberg BJ. Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy. Philos Transact A Math Phys Eng Sci. 2011;369(1955):4512–30. https://doi.org/10.1098/rsta.2011.0279.

29. Altoe ML, et al. Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy. Biomed Opt Express. 2019;10(8):4305–15. https://doi.org/10.1364/BOE.10.004305.

30. Chen JH, Yu HJ, Hsu C, Mehta RS, Carpenter PM, Su MY. Background parenchymal enhancement of the contralateral normal breast: association with tumor response in breast cancer patients receiving neoadjuvant chemotherapy. Transl Oncol. 2015;8(3):204–9. https://doi.org/10.1016/j.tranon.2015.04.001.

31. Preibisch H, et al. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response. Eur Radiol. 2016;26(6):1590–6. https://doi.org/10.1007/s00330-015-4011-x.

32. You C, et al. Association between background parenchymal enhancement and pathologic complete remission throughout the neoadjuvant chemotherapy in breast cancer patients. Transl Oncol. 2017;10(5):786–92. https://doi.org/10.1016/j.tranon.2017.07.005.

33. Oh SJ, Chae EY, Cha JH, Shin HJ, Choi WJ, Kim HH. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy. Br J Radiol. 2018;91(1088):20170550. https://doi.org/10.1259/bjr.20170550.

34. Leo GD, Trimbolli RM, Sella T, Sardanelli F. Optical imaging of the breast: basic principles and clinical applications. Am J Roentgenol. 2017;209(1):230–8. https://doi.org/10.2214/AJR.16.17220.

35. Noh JJ, Maskarinec G, Paganio M, Cheung LW-K, Stanczyk FZ. Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. Breast. 2006;15(1):20–8. https://doi.org/10.1016/j.breast.2005.04.014.

36. Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT. Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer. 2007;121(11):2506–11. https://doi.org/10.1002/ijc.22971.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.